Metro International Biotech, LLC

Janssen Pharmaceutica Nv

Alexion Pharmaceuticals, Inc.

Cyclacel Limited

Verona Pharma Plc

Philippe Fernandes

Andrew Carr

David J Livingston

Julian Scott Northen

Anjali Pandey

Sami Karaborni

Mark S Tichenor

Paul J Krawczuk

Ying Chen

Yuelie Lu

Gus Kodersha

Bertrand M C Plouvier

Michael J A Walker

Benjamin Mark Skead

Christopher Peter Worrall

Jonathan Charles Christian Atherton

The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.

Crystal forms of beta-nicotinamide mononucleotide

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK.

Small molecule inhibitors of the JAK family of kinases

Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms cerdulatinib and salts or co-crystals thereof.

Solid forms of Cerdulatinib

The invention relates to crystalline forms of a &#x3b2;-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.

Crystal forms of &#x3b2;-nicotinamide mononucleotide

Solid forms of cerdulatinib

The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumor activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.

Crystalline forms of a purine derivative

The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern. 

Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound

Growing community of inventors

Turnhout, Belgium

Philippe Fernandes